BriaCell Therapeutics Holds Security Holder Vote
Ticker: BCTXZ · Form: 8-K · Filed: Feb 6, 2025 · CIK: 1610820
Sentiment: neutral
Topics: shareholder-vote, corporate-governance
Related Tickers: BCTX
TL;DR
BriaCell shareholders voted on something important on Feb 5th.
AI Summary
BriaCell Therapeutics Corp. filed an 8-K on February 6, 2025, reporting on a meeting of security holders held on February 5, 2025. The filing indicates that matters were submitted to a vote of security holders.
Why It Matters
This filing signals that BriaCell Therapeutics Corp. is engaging its shareholders on important corporate decisions, which could impact the company's strategic direction.
Risk Assessment
Risk Level: low — The filing is a routine disclosure of a shareholder vote and does not contain information about significant financial changes or operational risks.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- February 5, 2025 (date) — Date of earliest event reported
- February 6, 2025 (date) — Date of report
FAQ
What specific matters were submitted for a vote by BriaCell Therapeutics Corp. security holders on February 5, 2025?
The filing states that 'Submission of Matters to a Vote of Security Holders' was the item reported, but does not detail the specific proposals voted upon.
What is the exact date of the report for this 8-K filing?
The exact date of the report is February 6, 2025.
What is BriaCell Therapeutics Corp.'s principal executive office address?
The principal executive offices are located at Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
What jurisdiction is BriaCell Therapeutics Corp. incorporated in?
BriaCell Therapeutics Corp. is incorporated in British Columbia.
What was BriaCell Therapeutics Corp.'s former company name?
The former company name was Ansell Capital Corp., with a date of name change on June 13, 2014.
Filing Stats: 750 words · 3 min read · ~3 pages · Grade level 10.8 · Accepted 2025-02-06 16:30:10
Filing Documents
- form8-k.htm (8-K) — 64KB
- 0001493152-25-005204.txt ( ) — 283KB
- bctx-20250205.xsd (EX-101.SCH) — 4KB
- bctx-20250205_def.xml (EX-101.DEF) — 29KB
- bctx-20250205_lab.xml (EX-101.LAB) — 36KB
- bctx-20250205_pre.xml (EX-101.PRE) — 26KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams February 6, 2025 William V. Williams President and Chief Executive Officer